Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAIBRAKHER phase 1 study of TAS0728 in HER2-aberrant solid tumors
jRCT2031240235Phase 1Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAS0728 in Nonhematologic neoplasms, bronchial carcinoma, breast cancer and 1 more, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity (DLT) in dose escalation part and Adverse events in dose expansion part. Started Aug 2024; status: active, not recruiting.
02
Drugs
TAS0728
03
Conditions
Nonhematologic neoplasmsbronchial carcinomabreast cancerGastric cancer (HER2-positive)
Beyond the preview
Go deeper on jRCT2031240235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240235.